Thus, these observations suggest that anti-RGMa antibody therapy effectively inhibited neurodegenerative processes in animal models of ALS and possesses therapeutic potential for treating patients with ALS by reducing SOD1 and ubiquitin aggregation. The gene discussed is RGMA; the disease is amyotrophic lateral sclerosis.